ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Analyst Earnings Estimates
NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10K | N/A -100.00% | 36.888M | -100.00% | 26.829M | 49.336M 83.89% | 178.91M 262.64% | 334.94M 87.21% | 365.05M 8.99% | 606.38M 66.11% | 812.36M 33.97% | |||||
| EBITDA YoY % growth | -23.73M | N/A -96.97% | -120.755M -153.81% | -239.408M -74.66% | -235.027M -9.01% | -274.865M -31.99% | -206.205M 30.83% | -255.749M -24.03% | -278.779M -9.01% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -23.78M | N/A -97.01% | -118.37M -153.55% | -238.764M -74.88% | -240.582M -9.41% | -297.03M -31.77% | -209.991M 29.89% | -257.125M -22.45% | -272.704M -6.06% | -240.69M 11.74% | -130.462M 45.80% | 12.547M 109.62% | 47.778M 280.79% | 274.59M 474.72% | 397.64M 44.81% | |
| Operating Margin | -237,800.00% | N/A | N/A | N/A | N/A | N/A | -569.27% | N/A | -1,016.45% | -487.86% | -72.92% | 3.75% | 13.09% | 45.28% | 48.95% | |
| EPS YoY % growth | N/A | N/A | -4.98 | -4.25 11.47% | -4.70 8.30% | -4.63 -2.43% | -2.50 46.04% | -2.99 -19.24% | -2.89 3.19% | -2.42 16.18% | -1.07 55.68% | 0.14 113.06% | 0.17 18.76% | 1.17 604.23% | 1.89 60.87% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.81 13.07% | -0.79 -666.83% | -0.80 35.18% | -0.79 -40.61% | -0.78 3.10% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -72.094M -8.36% | -73.358M -200.14% | -74.654M -15.75% | -75.97M -50.55% | -77.306M -7.23% |
| EBIT Q2Q % growth | -62.897M 7.40% | -60.319M -143.56% | -63.07M 3.19% | -64.6M -25.60% | -65.45M -4.06% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.56 29.11% | -0.93 | 0.37 | 39.67% |
| Q2 2024 Q2Q % growth | -1.24 32.97% | -0.86 | -0.38 | -44.57% |
| Q1 2024 Q2Q % growth | 0.14 113.08% | -0.78 | 0.92 | 117.90% |
| Q4 2023 Q2Q % growth | -0.93 -1.09% | -0.93 | 0.00 | 0.45% |
| Q3 2023 Q2Q % growth | -0.79 17.71% | -0.93 | 0.14 | 15.05% |
| Q2 2023 Q2Q % growth | -1.85 -38.06% | -1.06 | -0.79 | -74.82% |
| Q1 2023 Q2Q % growth | -1.07 18.32% | -1.04 | -0.03 | -2.90% |
| Q4 2022 Q2Q % growth | -0.92 17.12% | -1.08 | 0.16 | 14.92% |
| Q3 2022 Q2Q % growth | -0.96 23.20% | -1.19 | 0.23 | 19.48% |
| Q2 2022 Q2Q % growth | -1.34 | -1.21 | -0.13 | -10.81% |
| Q1 2022 Q2Q % growth | -1.31 -5.65% | -1.24 | -0.07 | -5.70% |
| Q4 2021 Q2Q % growth | -1.11 -9.90% | -1.52 | 0.41 | 27.21% |
| Q3 2021 Q2Q % growth | -1.25 -37.36% | -1.34 | 0.09 | 6.45% |
| Q2 2021 Q2Q % growth | -1.34 -71.79% | -1.20 | -0.14 | -12.12% |
| Q1 2021 Q2Q % growth | -1.24 56.94% | -0.99 | -0.25 | -25.59% |
| Q4 2020 Q2Q % growth | -1.01 | -0.97 | -0.04 | -3.79% |
| Q3 2020 Q2Q % growth | -0.91 | -0.82 | -0.09 | -10.60% |
| Q2 2020 Q2Q % growth | -0.78 | -0.51 | -0.27 | -51.93% |
| Q1 2020 Q2Q % growth | -2.88 | -0.71 | -2.17 | -303.36% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | 40.56M | 13.388M | 27.172M | 202.96% |
| Q1 2020 Q2Q % growth | 102K | -102K | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 24.74% | 0% | 18.09% |
| Revenue | N/A | N/A | 0% | 0.01% |